Recursion Pharmaceuticals Advances REC-994 in Cerebral Cavernous Malformation

Date

Share Now

Recursion Pharmaceuticals has completed a successful Phase 2 trial of REC-994 for treating cerebral cavernous malformation (CCM), marking progress in the development of treatments for this rare neurological condition. (September 5, 2024)

Source: Recursion Pharmaceuticals, Inc.

Tags :